China Biopharma, Inc., a biopharmaceutical company focused on developing and distributing human vaccine products in China, announced that it has signed a letter of intent (LOI) with HYTE Research LLC, a New Jersey-based biotechnology research company.

According to the agreement, the companies will jointly develop and commercialize Nano-Poly Enhancement technology for improving the effectiveness and reducing the side effects of human vaccines.

The resulting new technology will be used to combine with current human vaccines to achieve the immune-enhancing properties of surface antigen. Due to its superior field efficacy, this technology may be used to replace commonly used chemical adjuvants. An adjuvant is a substance that helps and enhances the pharmacological effect of a drug or increases the ability of an antigen to stimulate the immune system.

China Biopharma will utilize its existing platforms to conduct the development and commercialization of the new technology. According to the LOI, China Biopharma will hold 55% of the intellectual property rights on the technology.

Source:佚名